Loading
Chemotherapy leaves behind zombie cells that will not divide but poison their neighbours. Senolytics aim to clear them.
Therapy-induced senescent cells secrete inflammatory factors that promote relapse, drive fatigue, and accelerate ageing in survivors. Preclinically, a one-two punch of a senescence-inducing drug followed by a senolytic such as navitoclax improves outcomes. In humans, senolytic trials are concentrated in ageing, osteoporosis and neurodegeneration: a September 2026 registry search found no phase 2 senolytic study in cancer survivors. Navitoclax's thrombocytopenia limits dosing.
Senescent cells depend on anti-apoptotic BCL-2 family proteins to survive; BH3 mimetics, or dasatinib plus quercetin, kill them selectively.
Query for this technology: (TITLE:"Senolytics and senescence-directed therapy" OR ABSTRACT:"Senolytics and senescence-directed therapy") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Senolytics and senescence-directed therapy, not a curated reading list.
Shares Radical oncology: what could change the war by 2035, Cytotoxic chemotherapy and the tags frontier, radical.
Shares Paths to cures: interception, eradication, control, Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Cardio-oncology and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.